Commit Biologics

Leveraging the power of complement for cell depletion 

Commit Biologics is developing a new class of therapeutics redirecting the complement pathway towards diseased cells. Commit’s proprietary BiCETM platform, consisting of antibodies engineered to recruit complement components directly to target cells, leverages multiple mechanisms to drive rapid, selective, and T-cell independent cell depletion. The initial focus of the company is on depletion of B and T cells in cancer and autoimmune disease, with the ambition to build a comprehensive pipeline of first-in-class assets across multiple indications. The company was spun off from Aarhus University and is based in Copenhagen and Aarhus. 

 

Commit Biologics is backed by a syndicate of experienced life science investors including M Ventures, Ackermans & van Haaren, AbbVie Ventures, Novo Seeds, Bioqube Ventures, and Korys.